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While psychiatrists everywhere are doing 
their best to help people, their profession is 
in crisis. Psychiatry is struggling to defend 
itself from multiple sources of critique, and 
to reassert its future role. One possibility that 
is taboo for any profession to consider, how-
ever, is that it has little or no useful role. That 
possibility must be contemplated by others. 
An evidence based approach to evaluating 
what good psychiatry contributes to mental 
health services in the 21st century leads to 
some challenging conclusions.
Psychiatry’s crisis is evidenced in many 
ways. Most blatant is the international out-
pouring of criticism at the ﬁfth edition of the 
Diagnostic and Statistical Manual of Men-
tal Disorders [1], its latest attempt to catego-
rize human distress into discrete psychiatric 
‘disorders’. The fact that the attack on the 
poor science involved was led by the editor 
of the fourth edition [2], and the Director 
of the USA’s National Institute of Mental 
Health [3], was embarrassing.
It seems psychiatry is now held in low 
regard by other medical disciplines. Medical 
students in numerous countries are uninter-
ested in psychiatry as a career, seeing it as 
unscientiﬁc and ineffective [4]. In one study 
only 4–7% of UK medical students identi-
ﬁed psychiatry as a ‘probable/deﬁnite’ career 
choice, partly because of its poor empirical 
basis [4]. In a recent survey over 1000 non-
psychiatric medical faculty members, at 
universities in 15 countries, “did not view 
psychiatry as an exciting, rapidly expanding, 
intellectually challenging or evidence-based 
branch of medicine” ([5], page 24). A total 
of 90% believed that ‘Most psychiatrists are 
not good role models for medical students’. 
The most negative opinions were expressed 
by neurologists, pediatricians, radiologists 
and surgeons.
Even more revealing than the survey ﬁnd-
ings was psychiatry’s response to it. The 
researchers themselves, including a former 
President of the World Psychiatric Asso-
ciation, wondered whether their colleagues’ 
opinions are ‘well founded in facts’ or ‘may 
reﬂect stigmatizing views toward psychiatry 
and psychiatrists’. Their own answer to that 
question becomes abundantly clear when, 
instead of proposing efforts to address the 
problems identiﬁed by the medical commu-
nity, such as having little scientiﬁc basis, they 
recommend only ‘enhancing the perception of 
psychiatrists’ so as to ‘improve the perception 
of psychiatry as a career’ [5].
Similarly, all six responses to the survey, in 
the same edition of the journal, written by 
13 psychiatrists (including current and past 
Presidents of the European Psychiatric Asso-
ciation and the current President of the World 
Psychiatric Association) dismissed all the 
concerns raised by the 1057 medical experts 
and blamed everyone but their own profes-
sion, including their supposedly  ignorant, 
prejudiced medical colleagues and the biased 
media. The titles of these responses included 
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‘Overcoming stigmatizing attitudes toward psychia-
trists and psychiatry’ [6] and ‘Some thoughts on how to 
improve the image of psychiatry’ [7].
The journal editor did invite one response from out-
side the profession [8]. To that respondent, and to other 
commentators, the problem with these senior psychia-
trists’ response to criticism seemed obvious:
• “While all authors in their own different ways 
address what might be done to improve psychia-
try’s image, significantly, not a single psychiatrist 
thinks to ask what by humanistic standards would 
appear to be the compulsory question: Insofar as 
any of the bad image is deserved, exactly how are 
the ‘patients’ being ill served and what is owed 
them?” [9]; and
• “This strikes me as condescending to the point of 
arrogance, and, to the extent that it reflects psychi-
atric attitudes generally, could, in combination with 
psychiatry’s spurious foundations and destructive 
‘treatments,’ go a long way to explaining the nega-
tive  perceptions of other medical professions” [10]. 
One of the six responses [11] did acknowledge some 
fault on the part of the profession, but only in the past. 
The 1000 or so medical colleagues are, we are told, 
behind the times. One wonders, however, whether 
things are actually getting worse not better. Numerous 
prominent psychiatrists have recently been exposed 
engaging in unethical financial dealings with the 
 pharmaceutical industry [12–14].
A discipline claiming a central role should be contrib-
uting to three core research domains: conceptualization, 
causation and treatment. In terms of conceptualization, 
psychiatry’s primary contribution is an ever expanding 
list of labels [1]. Calling them ‘diagnoses’ cannot dis-
guise the fact that many do not reach minimal scientific 
reliability levels and have little or no predictive valid-
ity for outcome or treatment responsiveness [2,3,15,16]. 
For example, ‘schizophrenia’ – the flagship of biological 
psychiatry – requires just two of five symptoms, mean-
ing you can get this ‘diagnosis’ without having any-
thing in common with another person given the same 
‘diagnosis’ [15]. Such disjunctive constructs are instantly 
dismissed as unusable by real scientific disciplines. Even 
the USA’s National Institute of Mental Health, in its 
unceasing quest for the missing biological causes of 
human distress, has abandoned the diagnostic approach 
to classifying mental health problems and acknowledged 
the need to try to develop some scientifically robust 
‘research domains’ [3]. This is not just academic. Labels 
like ‘schizophrenia’ can, like the biogenetic causal beliefs 
that tend to accompany them, destroy lives, through 
prejudice, fear and  prognostic pessimism [17–19].
In terms of causation, psychiatry has focused pre-
dominantly on chemical imbalances, brain abnormali-
ties and genetics. The failure to provide any findings 
of substance [15,20–21] does not seem to matter. Merely 
engaging in this apparently scientific activity seems 
sufficient to sustain the ‘medical model’. Of course 
genetics is important but only if we research con-
structs that exist, using methodology that meets basic 
standards [21] and only if we acknowledge the role of 
epigenetic processes whereby genes are activated and 
deactivated by the environment [22]. The brain’s pri-
mary role is to respond to the environment but many 
psychiatrists appear unable to grasp this. Many still do 
not realize that brain differences between groups can 
be explained by the effects of childhood trauma on the 
developing brain [23].
In terms of treatment, research suggests that the 
safety and efficacy of psychiatric drugs have been 
grossly exaggerated [12–15,24–30]. For example, the lat-
est best estimates as to the percentage of people who 
benefit over and above placebo effects are 20% for 
antipsychotics and even less for antidepressants [24–26]. 
Furthermore, both antidepressants and antipsychotics 
have a range of well documented adverse effects, some 
of which are life threatening [12,13,15,25–27]. A survey of 
1829 people on antidepressants found the following 
rates: sexual difficulties (62%); feeling emotionally 
numb (60%), withdrawal effects (55%), feeling not 
like myself (52%), agitation (47%); reduction in posi-
tive feelings (42%), caring less about others (39%) and 
suicidality (39%) [27]. Despite clear evidence that anti-
psychotics can cause brain degeneration [25,28–29] and 
shorten life span [25,29,30], we still grant psychiatry, via 
mental health legislation, the right to force people to 
take them against their will. Drugs giant Otsuka has 
just applied to the US FDA to be able to insert a chip in 
Abilify so as to monitor ‘medication compliance’ [31].
Electroconvulsive treatment, which is undergoing a 
renaissance in countries most strongly dominated by 
biogenetic ideology, such as the USA and Australia, 
has no lasting benefit at all compared with placebo [32]. 
Unsurprisingly, it can cause long lasting or perma-
nent cognitive dysfunction, primarily in the form of 
 anterograde and retrograde amnesia [32].
Meanwhile, perhaps the most exciting develop-
ment in the field of ‘treatment’ is the hearing voices 
movement. While the evidence base for the efficacy of 
the hearing voices groups being run by voice hearers 
in 35 countries is in its infancy [33–35], the groups do 
“...research suggests that the safety and 
 efficacy of psychiatric drugs have been grossly 
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not cause stigma, pessimism, diabetes, brain damage, 
 suicide or shortened life span.
Despite all this, biological psychiatry is trying to 
expand the reach of what others consider to be an unsci-
entific, reductionist, simplistic and pessimistic ‘medical 
model’. Some psychiatrists have bemoaned what they 
call the poor ‘mental health literacy’ (i.e., one’s will-
ingness to agree with biological psychiatrists about the 
causes of human distress), not only of people in their 
own countries and cultures, but of people in numer-
ous ‘developing’ countries, including India, Pakistan, 
Bali, Nigeria and Malawi [18]. Terms like ‘misinfor-
mation’ and ‘lack of knowledge’ are used to describe 
spiritual and social causal beliefs. A typical conclusion 
is ‘Interventions aimed at increasing the mental health 
literacy of traditional healers are essential’ [36]. These 
 researchers consistently express concern that other 
 cultures’ beliefs limit the use of psychiatric drugs.
There is even an international organization, ‘Global 
Mental Health’, designed to bring the supposed supe-
riority of the Western approach to the rest of the 
world [37]. There seems to be no understanding that 
supplanting indigenous beliefs with those of a domi-
nant culture is a cornerstone of colonization. Also 
conveniently ignored are the findings of WHO stud-
ies that recovery rates for ‘schizophrenia’ are signifi-
cantly higher in ‘developing’ countries than in ‘devel-
oped’ countries [16,38]. Meanwhile, within the USA, 
researchers are alarmed that African–Americans insist 
on believing in ‘debunked theories of schizophrenia 
that focused on the family’s effect on causing schizo-
phrenia’ [39]; and bemoan the poor ‘psychosis literacy’ 
of Latinos, especially their failure to make ‘illness attri-
butions’ and their insistence that the ‘social world’ is 
important in understanding psychosis [40].
What role, if any, should be played by a profession 
whose research and thinking are so heavily influenced 
by drug companies [12–14] and which has produced 
so little of benefit to service users for 50 years? One 
potential role would be the traditional doctors’ func-
tion of attending to real medical illnesses. But even the 
official journal of the World Psychiatric Association 
has bemoaned the ‘suboptimal medical care’ provided 
by psychiatry [41], not to mention that some of service 
users’ most serious health conditions are caused by 
 psychiatric drugs.
Despite their relative inefficacy and dangerousness, 
psychiatric medications can be helpful (as a last resort, 
and for a short period). Therefore, mental health teams 
do need access to people with prescribing rights. So there 
is a useful role for psychiatrists, but only if they take an 
evidence-based approach, which concedes that a range 
of more effective and safer treatments should be offered 
first, that adverse effects should be fully disclosed and 
that no medical treatment should be forced on anyone 
against their will. In other medical  specialties forc-
ing a patient to receive a treatment  constitutes  ethical 
 misconduct and is severely  punished.
Finally, we should remember that the public, in other 
words users of mental health services, have a strong pref-
erence for psycho-social explanations and treatments. In 
24 of 25 countries where surveys have been conducted 
the public believes that social factors play a much greater 
role than genes or chemical imbalances in the etiology 
of mental health problems, with the only exception 
being the USA [42,43]. Similarly, in 14 out of 15 countries 
the public prefers talking therapies and social support 
to drugs or electroshock [42]. The evidence summarized 
above suggests that they may be right.
But is anyone paying attention to the public or 
the research? Currently, a lack of nonmedical staff 
– including peer support workers – especially in 
positions of leadership, is limiting the implementa-
tion and availability of nonpharmacological inter-
ventions. What would happen if managers, funders 
and politicians really took all this research evidence 
and public opinion into consideration when deciding 
what sort of services to provide and what sort of staff 
to employ?
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